(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 37.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Tg Therapeutics's revenue in 2025 is $386,386,000.On average, 3 Wall Street analysts forecast TGTX's revenue for 2025 to be $93,808,827,038, with the lowest TGTX revenue forecast at $91,206,514,487, and the highest TGTX revenue forecast at $97,348,588,075. On average, 3 Wall Street analysts forecast TGTX's revenue for 2026 to be $123,876,554,591, with the lowest TGTX revenue forecast at $109,953,896,689, and the highest TGTX revenue forecast at $141,895,251,177.
In 2027, TGTX is forecast to generate $160,973,320,118 in revenue, with the lowest revenue forecast at $140,453,914,205 and the highest revenue forecast at $182,393,660,860.